Connect Biopharma (CNTB) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Connect Biopharma (CNTB) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 51.6% versus a loss of 62.7%. Connect Biopharma is the larger company by market cap ($55.5 million vs $54.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | ZYBT |
|---|---|---|
| Share price | $0.8807 | $1.15 |
| Market cap | $55.46M | $54.50M |
| 1-day change | -6.77% | -0.87% |
| YTD return | -68.77% | -0.01% |
| 1-year return | -51.61% | -62.67% |
| 5-year return | -94.87% | — |
| EPS (TTM) | $-1.19 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $8.01 |
| 52-week low | $0.85 | $0.616 |
| Distance from 52-week high | -76.95% | -85.64% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +567.65% | — |
| Average volume | 3.81M | 5.10M |
| Shares outstanding | 62.97M | 47.39M |
| Employees | 64 | 269 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTB has outperformed ZYBT by 11.1 percentage points over the past year.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Healthcare · Biotechnology · 64 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Healthcare · Drug Manufacturers - Specialty & Generic · 269 employees
CNTB vs ZYBT FAQ
Which is bigger, Connect Biopharma or Zhengye Biotechnology?
Connect Biopharma (CNTB) is larger, with a market capitalization of $55.46M compared with $54.50M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, CNTB or ZYBT?
CNTB returned -51.61% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Zhengye Biotechnology in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Connect Biopharma and Drug Manufacturers - Specialty & Generic for Zhengye Biotechnology.